NCT00523549已完成4 期
A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 229
- 试验地点
- 1
- 主要终点
- Change in Lateral Mitral Annular Myocardial Relaxation Velocity
研究概览
简要总结
The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of <140 mmHg on the intrinsic diastolic properties of the myocardium in patients with hypertension and echocardiographic evidence of diastolic dysfunction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 45 years or older
- •Male and female patients are eligible. Female patients must be post-menopausal for one year, surgically sterile, or using effective contraceptive methods such as a double barrier method with spermicide, an intra-uterine device, or hormonal contraceptives. Post-menopausal women on a stable dose of hormone replacement therapy (HRT) for at least three (3) months prior to the screening visit are eligible for the study.
- •Uncontrolled systolic hypertension on a maximum of two (2) antihypertensive medications at the time of screening.
- •Echocardiographic ejection fraction ≥50% and evidence of diastolic dysfunction.
- •Provide written informed consent to participate in the study prior to any screening or study procedures
- •Have the ability to communicate well and comply with all study requirements
排除标准
- •Severe hypertension defined as a MSSBP >200 mmHg and/or MSDBP >120 mmHg.
- •History of a secondary cause of hypertension including but not limited to: coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc.
- •Ejection fraction <50 %
- •History of stroke, transient ischemic attack, myocardial infarction, coronary artery bypass graft surgery, or unstable angina pectoris within 6 months of screening
- •Presence of clinically significant ventricular or supraventricular arrhythmias (e.g. atrial fibrillation/flutter)
- •History of congestive heart failure
- •History of diabetes mellitus
- •History of renal impairment with serum creatinine >2.0 mg/dL at screening, history of dialysis, or history of nephritic syndrome
- •Antihypertensive therapy with three (3) or more medications at the time of screening
- •Active and/or treated malignancy of any organ system within twelve (12) months of enrollment, with the exception of localized basal cell carcinoma of the skin
- •Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/ml)
- •Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: barrier method with spermicidal agent, an intrauterine device, hormonal contraceptives, or total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Reliable contraception should be maintained throughout the study
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug including, but not limited to, any of the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active, or active inflammatory bowel syndrome within 12 months prior to Visit 1, currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction regarded as clinically meaningful by the investigator
- •Pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury within 12 months prior to Visit 1
- •Any serum AST or ALT elevation two (2) times the upper limit of normal
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
Standard treatment regimen
Experimental
(Valsartan + Amlodipine to target SBP of < 140 mmHg)
干预措施: valsartan (Drug)
Standard treatment regimen
Experimental
(Valsartan + Amlodipine to target SBP of < 140 mmHg)
干预措施: amlodipine (Drug)
Intensive treatment regimen
Experimental
(Valsartan + Amlodipine to target SBP < 130 mm Hg)
干预措施: valsartan (Drug)
Intensive treatment regimen
Experimental
(Valsartan + Amlodipine to target SBP < 130 mm Hg)
干预措施: amlodipine (Drug)
结局指标
主要结局
Change in Lateral Mitral Annular Myocardial Relaxation Velocity
时间窗: Baseline to 24 weeks after treatment
Change from baseline in lateral mitral annular myocardial relaxation velocity (E') at Week 24
次要结局
- Change in Estimated Central Aortic Pressure(Baseline to 8 and 24 weeks after treatment)
- Change in Left Atrial Size(Baseline to 24 weeks after treatment)
- Change in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity(Baseline to 24 weeks after treatment)
- Percent Change From Baseline in Vascular Stiffness(Baseline to 8 and 24 weeks after treatment)
- Change in Mean Sitting Systolic Blood Pressure (msSBP)(Baseline to 8 and 24 weeks after treatment)
- Change in Mean Sitting Diastolic Blood Pressure (msDBP)(Baseline to 8 and 24 weeks after treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With HypertensionHypertensionNCT00413049Novartis698
已完成
4 期
Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a DayHypertensionNCT00700271Novartis Pharmaceuticals478
已完成
3 期
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive PatientsHypertensionNCT00409643Novartis1,259
已完成
3 期
A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive PatientsHypertensionNCT00392262Novartis224
已完成
3 期
Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus FelodipineHypertensionNCT00367939Novartis132